Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Insider Buying

<< Previous

Bullboard Posts

Next >>

Comment by RjM2018on Feb 27, 2021 10:58pm

195 Views

Post# 32680576

RE:RE:RE: Insider Buying

Maybe they know something or maybe they just think the stock is severely undervalued at 6.38 (which it is!). There is a huge upside now. Started averaging down in 2015 after Phase 1 "fun"...going to try and add some more this week!

Just a random question, anyone know what AltaPharma International Inc is - see highlighted section below.

Filed 2021-02-27 16:43 Tx date 2021-02-23	$ATE Antibe Therapeutics Inc.	Wallace, John Lawrence 4 - Director of Issuer, 6 - Director or Senior Officer of 10% Security Holder, 5 - Senior Officer of Issuer Holder: AltaPharm International Inc. (Control or Direction)	Common Shares 11 - Acquisition or disposition carried out privately	$189,722 +29,737 vol $6.38 each	69,737